Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Cannula in Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 yr. with diagnostic criteria for severe sepsis, within 12 hours of admission in the Emergency Room, defined as hypotension after hemodynamic resuscitation, initial lactate \> 4, or persistence of organ dysfunction (oliguria \< 0.5 ml/kg/h, cyanosis, or altered consciousness).(qSOFA 1, 2 or 3)~Exclusion Criteria:~* Patients who require immediate ventilatory support both invasive and non-invasive, defined by severe hypoxemia (PaO2/FiO2 \< 150), severe tachypnea (40 x') with signs of respiratory fatigue or low level of consciousness (Glasgow \< 8).~* Patients with limitation of the therapeutic effort or orders of not CPR.~* Patients not susceptible to treatment with HFNC (facial trauma, tracheostomized, rejection of previous treatments with HFNC).~* Participation in other clinical trials that may affect survival.~* Home treatment with oxygen, CPAP or Non-invasive ventilation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- High-Flow nasal cannula (HFNC) (Type: EXPERIMENTAL): Treatment with HFNC will be adjusted for SpO2 \>92%, even with FiO2 of 0.21, if needed.~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow \>50 L/min is uncomfortable for many patients.~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat.
- Conventional therapy (Type: NO_INTERVENTION): Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 \< 92% by pulse oximetry.~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 \>95% without oxygen supply is acceptable. On the contrary, SpO2 \<92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).